Cystadenocarcinoma: Clinical Trials

11 trials for Cystadenocarcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 3 active not recruiting, 2 terminated, 1 recruiting. 11 Phase 2, 3 Phase 3, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 211Completed 4, Active not recruiting 3, Terminated 2, Recruiting 1, Unknown 1
Phase 33Completed 1, Terminated 1, Unknown 1
Phase 11Terminated 1

Follow Cystadenocarcinoma: new trials by email Literature Review of Cystadenocarcinoma trials Research Report on Cystadenocarcinoma

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
INCB099280, axitinib - Advanced Solid Tumors
Phase 1 / Phase 2TerminatedIncyte Corporation52024-04-162026-06-04
Study of Pembrolizumab Combination With Chemotherapy in Platinum-sensitive Recurrent Low-grade Serous Ovarian Cancer
Pembrolizumab - Ovarian Cancer, Low Grade Serous Carcinoma
Phase 2Active not recruitingNorth Eastern German Society of Gynaecological Oncology332022-02-222026-10-02
A Study of Azenosertib (ZN-c3) in Women With Recurrent or Persistent Uterine Serous Carcinoma
Azenosertib - Uterine Serous Carcinoma
Phase 2CompletedK-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc922021-07-282026-03-18
Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Niraparib - Endometrial Carcinoma, Serous Carcinoma
Phase 2RecruitingShandong University832021-06-012024-01-05
A Study of Various Treatments in Serous or p53 Abnormal Endometrial Cancer
External Beam Radiation, Niraparib, Vaginal high-dose rate brachytherapy - Endometrial Carcinoma, P53 Mutation
Phase 2 / Phase 3TerminatedUniversity Health Network, Toronto112020-11-172025-08-12
Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)
Platinum-Based Drug, Conventional chemotherapy - Ovarian Cancer, Ovarian Neoplasms
Phase 2 / Phase 3UnknownBlokhin's Russian Cancer Research Center1642019-09-012019-08-13
Ribociclib and Letrozole Treatment in Ovarian Cancer
Ribociclib, Letrozole - Low Grade Serous Carcinoma
Phase 2Active not recruitingGynecologic Oncology Group512019-05-202025-12-23
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Biospecimen Collection, Computed Tomography, Echocardiography Test - Acinar Cell Carcinoma, Adenoid Cystic Carcinoma
Phase 2Active not recruitingNational Cancer Institute (NCI)7982017-01-302026-06-17
Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer
Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma
Phase 2 / Phase 3CompletedNational Cancer Institute (NCI)2602014-04-112026-08-04
Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer
Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib - Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma
Phase 2CompletedNational Cancer Institute (NCI)522007-12-172020-12-03
Papillary Serous Carcinoma of the Endometrium
Paclitaxel, Pelvic Radiation, Dexamethasone - Endometrial Cancer
Phase 2CompletedM.D. Anderson Cancer Center302001-04-012014-07-03

Narrower conditions

Cystadenocarcinoma, Serous (11)  ·  Endometrial Neoplasms (3)  ·  Ovarian Neoplasms (3)  ·  Adenocarcinoma, Mucinous (2)  ·  Carcinosarcoma (2)  ·  Fallopian Tube Neoplasms (2)  ·  Vulvar Neoplasms (2)  ·  Adenocarcinoma, Bronchiolo-Alveolar (1)  ·  Adrenocortical Carcinoma (1)  ·  Bile Duct Neoplasms (1)  ·  Carcinoma, Acinar Cell (1)  ·  Carcinoma, Adenoid Cystic (1)  ·  Carcinoma, Basal Cell (1)  ·  Carcinoma, Endometrioid (1)  ·  Carcinoma, Giant Cell (1)

Broader conditions

Adenocarcinoma (11)  ·  Carcinoma (11)  ·  Neoplasms (11)  ·  Neoplasms by Histologic Type (11)  ·  Neoplasms, Cystic, Mucinous, and Serous (11)  ·  Neoplasms, Glandular and Epithelial (11)  ·  Female Urogenital Diseases (7)  ·  Female Urogenital Diseases and Pregnancy Complications (7)  ·  Genital Diseases (7)  ·  Genital Diseases, Female (7)  ·  Genital Neoplasms, Female (7)  ·  Neoplasms by Site (7)  ·  Urogenital Diseases (7)  ·  Urogenital Neoplasms (7)

Interventions

Letrozole (2)  ·  Paclitaxel (2)  ·  niraparib (2)  ·  AZD 6244 (1)  ·  Axitinib (1)  ·  CTLA-4 Antigen (1)  ·  Cimetidine (1)  ·  Dexamethasone (1)  ·  Diphenhydramine (1)  ·  Doxorubicin (1)  ·  Ipilimumab (1)  ·  Magnetic Resonance Spectroscopy (1)  ·  Nivolumab (1)  ·  Specimen Handling (1)  ·  Tamoxifen (1)

Sponsors

National Cancer Institute (NCI) (3)  ·  Blokhin's Russian Cancer Research Center (1)  ·  Gynecologic Oncology Group (1)  ·  Incyte Corporation (1)  ·  K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc (1)  ·  M.D. Anderson Cancer Center (1)  ·  North Eastern German Society of Gynaecological Oncology (1)  ·  Shandong University (1)  ·  University Health Network, Toronto (1)

Countries

United States (6)  ·  Canada (2)  ·  United Kingdom (2)  ·  Australia (1)  ·  China (1)  ·  Georgia (1)  ·  Germany (1)  ·  Guam (1)  ·  Russia (1)

Top investigators

Amit Oza, MD (1)  ·  Anuja Jhingran, MD (1)  ·  Brian Slomovitz, MD (1)  ·  David M Gershenson (1)  ·  John H Farley (1)  ·  Philomena Colucci (1)  ·  Sandip P Patel (1)

Results publications

PMID 23261356, PMID 23385150, PMID 31969335, PMID 33362722, PMID 33882143, PMID 34380663, PMID 34716198, PMID 35123694, PMID 38243705, PMID 38358334, PMID 39067873, PMID 39343510, PMID 39417692, PMID 39583952, PMID 39856213, PMID 40402690, PMID 40588371, PMID 41108824, PMID 41672597, PMID 41892875, PMID 41995270, PMID 42499790

NIH funding

U10CA180868 (2), 2023 (1), P50CA083639 (1), U10CA027469 (1), U10CA180888 (1)